{"id":10824,"date":"2022-11-09T05:54:07","date_gmt":"2022-11-09T05:54:07","guid":{"rendered":"https:\/\/marylanddailygazette.com\/obesity-pipeline-analysis-120-companies-are-working-to-improve-the-treatment-space-delveinsight\/"},"modified":"2022-11-09T05:54:07","modified_gmt":"2022-11-09T05:54:07","slug":"obesity-pipeline-analysis-120-companies-are-working-to-improve-the-treatment-space-delveinsight","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/obesity-pipeline-analysis-120-companies-are-working-to-improve-the-treatment-space-delveinsight\/","title":{"rendered":"Obesity Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight"},"content":{"rendered":"<p><a href=\"https:\/\/www.digitaljournal.com\/pr\/obesity-pipeline-analysis-120-companies-are-working-to-improve-the-treatment-space-delveinsight\">Obesity Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight<\/a><\/p>\n<p><div><a href=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/11\/UuvHM4.png\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Obesity Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/11\/UuvHM4.png\" alt=\"Obesity Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight\" width=\"225\"><\/a><\/div>\n<p>DelveInsight\u2019s, \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Obesity Pipeline Insight<\/a>, 2022,\u201d report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p><strong>Key takeaways from Obesity Pipeline Insight Report<\/strong><\/p>\n<ul>\n<li>DelveInsight\u2019s <strong>Obesity <\/strong>Pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for <strong>Obesity<\/strong>.<\/li>\n<li>The leading Obesity Companies such as Novartis, Eli Lily &amp;Company, Scohia Pharma, ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Boehringer Ingelheim, Pfizer, and others are evaluating novel <strong>Obesity <\/strong>treatment drugs candidate to improve the treatment landscape.<\/li>\n<li>Promising Obesity Therapies such as VI-0521, THR-4109, PF-06882961, Rosuvastatin, Midazolam, Tirzepatide, Tesofensine, and others.<\/li>\n<li>The companies and academics are working to assess challenges and seek opportunities that could influence Obesity R&amp;D. The therapies under development are focused on novel approaches to treat\/improve Obesity.<\/li>\n<li>In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obesity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/li>\n<\/ul>\n<p><strong>Request a sample and discover the recent advances in Obesity treatment @ <a href=\"https:\/\/www.delveinsight.com\/report-store\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Obesity Pipeline Report<\/a><\/strong><\/p>\n<p><strong>Obesity Overview<\/strong><\/p>\n<p>Obesity can be described as the \u201cNew World Syndrome\u201d. Obesity is a multi-factorial disorder, which is often associated with many other significant diseases such as diabetes, hypertension and other cardiovascular diseases, osteoarthritis and certain cancers. The management of obesity will therefore require a comprehensive range of strategies focussing on those with existing weight problems and also on those at high risk of developing obesity. Hence, prevention of obesity during childhood should be considered a priority, as there is a risk of persistence to adulthood. Its prevalence is on continuous rise in all age groups of many of the developed countries in the world. Obesity, in simple terms, may be defined as a state of imbalance between calories ingested versus calories expended which would lead to excessive or abnormal fat accumulation. Obesity is not a single disorder but a heterogeneous group of conditions with multiple causes each of which is ultimately expressed as obese phenotype.<\/p>\n<p><strong>Recent Breakthroughs of Obesity Treatment Landscape<\/strong><\/p>\n<ul>\n<li>Tirzepatide also known as LY3298176, (Dual GIP\/GLP-1 Receptor Agonist) is a biologic entity that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of obesity. The dual agonist has also proven to be efficacious in tackling obesity and cardiovascular risk factors associated with T2D.<\/li>\n<li>Danuglipron (formerly PF 06882961) is an orally administered, small molecule, glucagon-like peptide 1 receptor (GLP 1R) agonist, being developed by Pfizer. The drug is currently in phase 2 stage of development for the treatment of obesity.<\/li>\n<li>XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog developed at Sciwind Biosciences. It has been shown to be safe and well tolerated, and induced dose-dependent weight reductions in early clinical trials. . The drug is currently in phase 2 stage of development for the treatment of obesity.<\/li>\n<li>Noiiglutide is a glucagon-like peptide-1 (GLP-1) analogue being developed by Jiangsu Hansoh Pharmaceutical for the treatment of obesity. Currently, it is in phase 2 stage of development.<\/li>\n<\/ul>\n<p><strong>Find out more about Obesity Medication @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Obesity Treatment<\/a><\/strong><\/p>\n<p><strong>Obesity Emerging Drugs<\/strong><\/p>\n<ul>\n<li>Tirzepatide: Eli Lily &amp; Company<\/li>\n<li>Danuglipron: Pfizer<\/li>\n<li>XW003: Sciwind Biosciences<\/li>\n<li>Noiiglutide: Jiangsu Hansoh Pharmaceutical<\/li>\n<li>MEDI 0382: MedImmune<\/li>\n<\/ul>\n<p><strong>DelveInsight\u2019s Obesity Pipeline Report covers around 120+ products under different phases of clinical development like<\/strong><\/p>\n<ul>\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p><strong>Learn more about the novel and emerging Obesity pipeline therapies @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Obesity Clinical Trials<\/a><\/strong><\/p>\n<p><strong>Scope of the Obesity Pipeline Insight Report<\/strong><\/p>\n<ul>\n<li>Coverage- Global<\/li>\n<li><strong>Obesity <\/strong>Assessment by Product Type<\/li>\n<li><strong>Obesity <\/strong>Assessment by Stage and Product Type<\/li>\n<li><strong>Obesity <\/strong>Assessment by Route of Administration<\/li>\n<li><strong>Obesity <\/strong>Assessment by Stage and Route of Administration<\/li>\n<li><strong>Obesity <\/strong>Assessment by Molecule Type<\/li>\n<li><strong>Obesity <\/strong>Assessment by Stage and Molecule Type<\/li>\n<li><strong>Obesity Companies- <\/strong>Novartis, Eli Lily &amp;Company, Scohia Pharma, ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Boehringer Ingelheim, Pfizer, and others are evaluating novel <strong>Obesity <\/strong>treatment drugs candidate to improve the treatment landscape.<\/li>\n<li>Obesity Therapies- VI-0521, THR-4109, PF-06882961, Rosuvastatin, Midazolam, Tirzepatide, Tesofensine, and others<\/li>\n<\/ul>\n<p><strong>Table of Content<\/strong><\/p>\n<ol start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Obesity: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Obesity\u2013 DelveInsight\u2019s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Tirzepatide: Eli Lily &amp; Company<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<\/ol>\n<p>10. Danuglipron: Pfizer<\/p>\n<p>11. Initial Stage Products (Phase I)&nbsp;<\/p>\n<p>12. Drug name: Company name<\/p>\n<p>13. Preclinical and Discovery Stage Products&nbsp;<\/p>\n<p>14. Drug name: Company Name<\/p>\n<p>15. Inactive Products<\/p>\n<p>16. Obesity Key Companies<\/p>\n<p>17. Obesity Key Products<\/p>\n<p>18. Obesity- Unmet Needs<\/p>\n<p>19. Obesity- Market Drivers and Barriers<\/p>\n<p>20. Obesity- Future Perspectives and Conclusion<\/p>\n<p>21. Obesity Analyst Views<\/p>\n<p>22. Obesity Key Companies<\/p>\n<p>23. Appendix<\/p>\n<p><strong>Dive deep into rich insights for drugs for Obesity treatment, visit @ <a href=\"https:\/\/www.delveinsight.com\/sample-request\/obesity-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">New Drug for Obesity Treatment<\/a><\/strong><\/p>\n<p><strong>About Us<\/strong><\/p>\n<p>DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span>Media Contact<\/span><br \/><strong>Company Name:<\/strong> DelveInsight Business Research LLP<br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"http:\/\/www.universalpressrelease.com\/?pr=obesity-pipeline-analysis-120-companies-are-working-to-improve-the-treatment-space-delveinsight&amp;type=pra\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=obesity-pipeline-analysis-120-companies-are-working-to-improve-the-treatment-space-delveinsight\" alt width=\"1px\" height=\"1px\"><\/p>\n<p>Published Tue, 08 Nov 2022 20:10:19 -0600<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Obesity Pipeline Analysis: 120+ Companies are Working to Improve the Treatment Space | DelveInsight DelveInsight\u2019s, \u201cObesity Pipeline Insight, 2022,\u201d report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":10823,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10824"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=10824"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10824\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/10823"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=10824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=10824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=10824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}